Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the second most common cause of cancer-related mortality worldwide. More than 600 000 people are newly diagnosed each year, and approximately the same number die annually.
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related mortality worldwide. The expression of nitric oxide synthase (NOS) and the inhibition of autophagy have been linked to cancer cell death. However, the involvement of serum nitric oxide (NO), the expression of NOS and autophagy have not been investigated in HCC. In the present study, we first established that the NO level was significantly higher in hepatitis B virus-related HCC than in the liver cirrhosis control (53.60 ± 19.74 vs 8.09 ± 4.17 μmol/L, t = 15.13, P < 0.0001). Using immunohistochemistry, we found that the source of NO was at least partially attributed to the expression of inducible NOS and endothelial NOS but not neuronal NOS in the liver tissue. Furthermore, in human liver cancer cells, NO-induced apoptosis and inhibited autophagy. Pharmacological inhibition of autophagy also induced apoptosis, whereas the induction of autophagy could ameliorate NO-induced apoptosis. We also found that NO regulates the switch between apoptosis and autophagy by disrupting the Beclin 1/Vps34 association and by increasing the Bcl-2/Beclin 1 interaction. Overall, the present findings suggest that increased NOS/NO promotes apoptosis through the inhibition of autophagy in liver cancer cells, which may provide a novel strategy for the treatment of HCC.
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Nitric oxide (NO) is a ubiquitous, short-lived physiological mes-
senger that plays important roles in modulating tumor growth progression and carcinogenesis. 10 In liver cancer, the expression pattern of NOS remains unknown. One study investigated iNOS expression in cancer tissue and pair-matched non-tumor liver tissue and found lower iNOS expression in HCC. 11 However, in the aforementioned study, iNOS expression in HCC was not compared to that in cirrhosis patients without HCC, because most of the HCC cases developed in the background of cirrhosis. Moreover, eNOS and nNOS, which are also important for NO synthesis, were not tested in parallel.
Therefore, the NOS expression and serum NO levels need to be further investigated in patients with HCC.
Nitric oxide modulates different cancer-related events including apoptosis, cell cycle progression, invasion and metastasis. 12 NO is being intensively investigated for therapeutic purposes; NO donors or NO inhibitors are used alone or in combination with other cytotoxic agents. In rat hepatoma cells 13 and cultured rat hepatocytes, 14 NO increased cell death. However, there is considerable controversy and confusion regarding its role in HCC, at least in part due to a lack of data directly from cancer patients. 
| NO concentration detection
To determine NO levels in cirrhosis patients and HCC patients, a
Griess assay (Qiagen, Hilden, Germany) was performed using plasma by strictly following the manufacturer's instructions.
| Immunohistochemical staining of iNOS, eNOS, nNOS and p62
Tumor samples free of necrosis or hemorrhage upon macroscopic inspection were selected, fixed in 4% paraformaldehyde and em- 
| Evaluation of iNOS, eNOS and nNOS expression
To score the staining of iNOS, eNOS and nNOS, only noticeable 0-3 was defined as negative and 4 or higher was defined as positive. Cleared lysates were separated on 14% Tris-glycine gels or 8%-13%
| Quantitation of apoptosis

| Immunoblot
Bis-Tris gels (Invitrogen, Carlsbad, CA, USA) followed by being transferred to nitrocellulose. After blocking with 5% skim milk, blots were probed using the following primary antibodies: rabbit anti-LC3 (Cell Signaling, Boston, MA, USA) or SQSTM1/p62 (Novus Biologicals).
Bands were detected using horseradish peroxidase-labeled secondary antibodies. Blots were developed using an enhanced chemiluminescence detection system.
| Statistical analysis
The results are expressed as the mean ± standard deviation.
Statistical analyses were performed using SPSS software 13.0.
Student's t-test or a one-way ANOVA followed by Tukey's or Kruskal-Wallis post-hoc tests, depending on the data distribution, were used for comparing the differences in variables between the HCC and control groups. The reported P-values are two-sided, and P < 0.05 was considered statistically significant. (Figure 1 ).
| RE SULTS
| Serum NO levels increased in HCC
| Source of NO
Endogenous NO production is tightly regulated by the activity of NOS. Thus, we tested the in vivo expression of NOS in tissue.
Negative immunostaining ( Figure S1 ) was observed in liver tissues of patients with cirrhosis and patients with HCC when we immunostained with a specific antibody against nNOS. The negative staining was not attributed to the incompetency of the antibody, be- 
| NO induces apoptosis in HepG2 cells
Among all the NO donors, sodium nitroprusside (SNP) is the only compound approved for human use and thus was selected for subsequent experiments. By using DAPI staining, the effect of NO on apoptosis in human HCC cells was assessed. As shown in Figure S2 , NO induces apoptosis in HCC cells in a dose-and time-dependent manner. We selected 100 μmol/L and 24 hours for the subsequent treatment for more potent effects.
Next, we tested whether NO induces HCC cell apoptosis through autophagy. CQ is a lysosomotropic drug that raises the intralysosomal pH and impairs autophagic protein degradation. CQ treatment also leads to apoptotic changes in HepG2 cells (Figure 3 ).
Rapamycin, a drug that induces autophagy by inhibiting mammalian target of rapamycin (mTOR), protected HepG2 cells from NOinduced apoptosis (Figure 3 ).
| NO inhibits autophagy
Nitric oxide is a multipotent mediator and its effect on autophagy largely depends on the cell type and cellular environment. In HEK293 cells, NO inhibits autophagy, 17 whereas NO induces autophagy in melanoma cells. 18 To date, no data have reported the However, after incubation with SNP at 100 nmol/L for 24 hours, a decrease in both GFP puncta and colocalization of GFP and RFP F I G U R E 1 Serum nitric oxide (NO) levels increased in hepatocellular carcinoma (HCC). Plasma from hepatitis B virusrelated HCC patients and cirrhosis patients were tested for nitrite (end product of NO) using the Griess reaction. The NO level in the HCC patients was significantly higher than that in the cirrhosis patients. **P < 0.01. LC, liver cirrhosis fluorescence were observed, suggesting an inhibition of autophagy.
Together, these data support the idea that NO inhibits autophagy flux in liver cancer cells.
| NO increases Beclin 1-Bcl2 interaction and reduces Beclin 1-hVps34 interaction
Nitric oxide induces apoptosis and autophagy. Beclin 1, the mammalian ortholog of yeast Atg6, interacts with several cofactors and regulates the switch between apoptosis and autophagy. Beclin 1 is a molecular switch that induces autophagy when it binds to Vps34, whereas it prompts apoptosis and inhibits autophagy when it binds to Bcl-2 and disrupts the Beclin 1/Vps34 complex. We tested whether NO regulates the Beclin 1/Bcl2 and Beclin 1/Vps34 interactions.
After treatment with the NO donor SNP, the binding of Bcl-2 to Figure 5C ), suggesting that the inhibitory effects of NO on autophagy were due to a decreased association of hVps34 with Beclin 1 that disrupted the initiation of autophagosome formation.
| Autophagy was inhibited in liver cancer
Our in vivo data exhibited that NO is implicated in HCC, and our in vitro data showed that NO inhibits autophagy and promotes apoptosis in hepatocytes, raising the question of whether in vivo autophagy in hepatocytes is inhibited. Thus, we investigated the autophagy activity in liver tissue from patients with HCC. As shown in Figure 6 , both in cancerous tissue and tissue adjacent to liver cancer, hepatocytes displayed low autophagic activity, as manifested by increased p62.
F I G U R E 2 Endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) expression in liver tissues. Immunohistochemical eNOS and iNOS staining were conducted using human cirrhosis liver tissue, hepatocellular carcinoma (HCC) tissue and HCC paracancerous tissue. Weighted scores were produced by multiplying the percentage scores of the positive tumor cell area by the staining intensity scores (degree × extent) (original magnifications ×100 and ×200). LC, liver cirrhosis
| D ISCUSS I ON
It has been known for many years that NO plays an important pro-survival/pro-apoptosis role in various tumors. 22 short, approximately 1 second, the NO level in the liver tissue is largely dependent on NOS expression. As shown in Figure 2 , the expression of NOS is highly inhomogeneous. In HCC, the tumor may outgrow its blood supply, and the center of the tumor, the area with the poorest blood supply, may undergo necrosis and thus contain the lowest level of NO. However, the blood supply of the surrounding areas will be much higher and will thus have a relatively high NO level.
One of the interesting issues in this study is the identification of the source of NO in HCC. In mammals, three distinct genes encode the NOS isoenzymes, neuronal (nNOS or NOS-1), inducible (iNOS or NOS-2) and endothelial (eNOS or NOS-3) genes. 24 nNOS is exclusively present in peripheral nerves and, consistently, nNOS was completely absent from patients with cirrhosis and patients with HCC. eNOS is constitutively present in vascular endothelial cells.
During the pathophysiological process of HCC, an increase in vascularity is very common. Consistent with an increased serum NO level, our data showed that there was a marked increase in eNOS immunoreactivity. iNOS, produced mainly in pathological conditions by mesenchymal cells and parenchymal cells through the stimulation of endotoxin and cytokines, is expressed under transcriptional and post-transcriptional control. Our study also showed that iNOS was highly expressed in cancer tissue. Therefore, the systemic increase in NO in HCC patients could be due, at least partially, to the overexpression of eNOS and iNOS but not nNOS. or through the initiation of apoptosis in the cancer cell. 28 NADPH oxidase and related enzymes also participate in important cellular processes that are directly related to host defense, including signal F I G U R E 6 Autophagy was inhibited in the liver tissues of hepatocellular carcinoma (HCC) patients. Immunohistochemical SQSTM1/p62 staining was conducted using human cirrhosis liver tissue, HCC tissue and HCC paracancerous tissue. The weighted scores were produced by multiplying the percentage scores for the positive tumor cell area by the staining intensity scores (degree × extent). Original magnification ×100 and ×200. LC, liver cirrhosis transduction, cell proliferation and apoptosis. 29 ROS, through their ability to induce cellular senescence and apoptosis, was harmful to tumor cells. 30 We hypothesize that NOS/NO may form another important anti-cancer host defense response, which may be a good approach for treating cancer.
We have shown that overexpression of eNOS and iNOS but not nNOS in cancer tissue contributes to increased NO levels in patients with HCC. We also found that NO inhibits autophagy by disrupting the Beclin 1/Vps34 association and promotes apoptosis by increasing the Bcl-2/Beclin 1 interaction in liver cancer cells. Our findings suggest that increased NO/NOS levels regulate autophagy and apoptotic cell death in HCC. 
ACK N OWLED G EM ENTS
CO N FLI C T O F I NTE R E S T
The authors declare that they have no competing interests.
O RCI D
Li Jin
https://orcid.org/0000-0002-4648-0500
